Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Authors: William D. Tap, Robin L. Jones, Brian A. Van Tine, Bartosz Chmielowski, Anthony Elias, Douglas Adkins, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory Pennock, Meera Hameed, Gaurav Shah, Amy Qin, Ashwin Shahir, Damien M. Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz - The Lancet 2016 cited by 588